Cough In Idiopathic Pulmonary Fibrosis (IPF) - Pipeline Insight,2025

This “Cough in Idiopathic Pulmonary Fibrosis (IPF) - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cough in Idiopathic Pulmonary Fibrosis (IPF): Understanding

Cough in Idiopathic Pulmonary Fibrosis (IPF): Overview

Chronic cough is a common and debilitating symptom experienced by most patients with idiopathic pulmonary fibrosis (IPF). The pathophysiology of cough in IPF is multifactorial, involving alterations in mucous production and clearance, architectural distortion of the lungs, and increased cough reflex sensitivity. Modifiable comorbidities like gastroesophageal reflux disease, chronic obstructive pulmonary disease, and obstructive sleep apnea can also contribute to cough. Cough in IPF is typically dry and tickly, triggered by various factors, and can lead to a vicious cycle of further irritation and mucus production. While there are no approved treatments specifically for IPF cough, potential therapies include proton pump inhibitors for acid reflux, inhaled steroids for eosinophilic cough, and opioids like morphine for cough hypersensitivity.

Chronic cough is a common and distressing symptom in patients with idiopathic pulmonary fibrosis (IPF), affecting up to 80% of people with the disease. The cough is often dry and persistent, and usually gets worse over time. The pathogenesis of cough in IPF is likely multifactorial, influenced by mechanical, biochemical, and neurosensory changes in the lungs, as well as comorbidities like gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), chronic sinusitis, and lung cancer. Chronic cough in IPF is often refractory to typical over-the-counter cough medications and can significantly impair quality of life for patients with this progressive lung disease.

In the diagnostic journey of Idiopathic Pulmonary Fibrosis (IPF), cough serves as a prominent symptom, often manifesting as dry and persistent. While cough alone is nonspecific, in conjunction with other clinical findings such as exertional dyspnea and bibasilar inspiratory crackles on auscultation, it can raise suspicion for IPF. It's crucial for clinicians to conduct a comprehensive evaluation, including imaging studies like high-resolution computed tomography (HRCT) of the chest, pulmonary function tests (PFTs), and in some cases, surgical lung biopsy, to confirm the diagnosis. Additionally, ruling out alternative etiologies of interstitial lung disease (ILD) is essential for accurate management and prognosis determination in IPF patients.

Treatment for chronic cough in idiopathic pulmonary fibrosis (IPF) is often challenging due to its refractory nature. Conventional anti-tussive therapy is often ineffective, and oral corticosteroids have shown some benefit in a small study. Low doses of prednisone may be tried to relieve cough symptoms, but their impact on quality of life and survival is uncertain. Opiates are not proven to be effective in IPF, although they may be considered for palliation in advanced cases. Thalidomide has been shown to improve quality of life in a small study, but its side-effect profile is concerning. The two available anti-fibrotic drugs, pirfenidone and nintedanib, may also have a positive effect on cough, although this has not been formally evaluated. Other approaches, such as mucolytic therapy for mucus productive coughs, and addressing comorbidities like acid reflux and postnasal drip, are also important in managing the cough.

'Cough in Idiopathic Pulmonary Fibrosis (IPF)- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline landscape is provided which includes the disease overview and Cough in Idiopathic Pulmonary Fibrosis (IPF) treatment guidelines. The assessment part of the report embraces, in depth Cough in Idiopathic Pulmonary Fibrosis (IPF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cough in Idiopathic Pulmonary Fibrosis (IPF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cough in Idiopathic Pulmonary Fibrosis (IPF) R&D. The therapies under development are focused on novel approaches to treat/improve Cough in Idiopathic Pulmonary Fibrosis (IPF).

Cough in Idiopathic Pulmonary Fibrosis (IPF) Emerging Drugs Chapters

This segment of the Cough in Idiopathic Pulmonary Fibrosis (IPF) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cough in Idiopathic Pulmonary Fibrosis (IPF) Emerging Drugs

Haduvio (nalbuphine ER): Trevi Therapeutics

Haduvio (nalbuphine ER) has a novel approach to chronic cough by working on two important receptors that are critical mediators of cough, in both the central and peripheral nerves. Haduvio has a dual mechanism of action, acting as both an agonist (activator) to the kappa opioid receptor and as an antagonist (blocker) to the body’s mu opioid receptor. By targeting these receptors along the complete cough pathway, it has the potential to work regardless of whether the initial cough trigger originates in the lung or in the central nervous system. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF).

Cough in Idiopathic Pulmonary Fibrosis (IPF): Therapeutic Assessment

This segment of the report provides insights about the different Cough in Idiopathic Pulmonary Fibrosis (IPF) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cough in Idiopathic Pulmonary Fibrosis (IPF)

• There are approx. 5+ key companies which are developing the therapies for Cough in Idiopathic Pulmonary Fibrosis (IPF). The companies which have their Cough in Idiopathic Pulmonary Fibrosis (IPF) drug candidates in the most advanced stage, i.e. Phase II include, Trevi Therapeutics.

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cough in Idiopathic Pulmonary Fibrosis (IPF): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Cough in Idiopathic Pulmonary Fibrosis (IPF) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cough in Idiopathic Pulmonary Fibrosis (IPF) drugs.

Cough in Idiopathic Pulmonary Fibrosis (IPF) Report Insights

• Cough in Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cough in Idiopathic Pulmonary Fibrosis (IPF) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cough in Idiopathic Pulmonary Fibrosis (IPF) drugs?
• How many Cough in Idiopathic Pulmonary Fibrosis (IPF) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cough in Idiopathic Pulmonary Fibrosis (IPF) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cough in Idiopathic Pulmonary Fibrosis (IPF) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Trevi Therapeutics
• Algernon Pharmaceuticals
• Melius Pharma

Key Products

• Haduvio (nalbuphine ER)
• Ifenprodi
• ME-015

This product will be delivered within 2 business days.